Dr. Reddy’s Laboratories announces the launch of Daptomycin for Injection, 500mg/vial single-dose vial in the U.S. Market
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--May 15, 2019--
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Daptomycin for Injection, 500mg/vial single-dose vial, a therapeutic equivalent generic version of Cubicin ® for Injection, approved by the U.S. Food and Drug Administration (USFDA).
The Cubicin ® for Injection (daptomycin for injection) brand and generic had U.S. sales of approximately $640.8 million MAT for the most recent twelve months ending in March 2019 according to IQVIA Health*.
Dr. Reddy’s Daptomycin for Injection is available in single-dose 15 ml vials containing 500 mg of daptomycin.
Cubicin is a trademark of Merck Sharp & Dohme Corp.
*IQIA Retail and Non-Retail MAT March 2019
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com.
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.
The company assumes no obligation to update any information contained herein.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190514006143/en/
CONTACT: INVESTOR RELATIONS
(PH: +91-40-49002135)MEDIA RELATIONS
(PH: +91-40- 49002121)
KEYWORD: UNITED STATES ASIA PACIFIC NORTH AMERICA NEW JERSEY NEW YORK INDIA
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL GENERAL HEALTH
SOURCE: Dr. Reddy’s Laboratories Ltd.
Copyright Business Wire 2019.
PUB: 05/15/2019 01:59 AM/DISC: 05/15/2019 01:59 AM